Major Histocompatibility Complex class I-peptide complex (MHC-I-peptide complex) (MHC-I-peptide complex)

The Major Histocompatibility Complex (MHC) class I-peptide complex is a fundamental molecular assembly that presents intracellularly derived peptides to the adaptive immune system [1]. In the context of Acute Myeloid Leukemia (AML), these complexes on the surface of AML blasts display leukemia-associated antigens (LAAs), such as WT1 or PRAME, which serve as specific markers for immune recognition [3]. Therapeutic approaches using autologous dendritic cells involve harvesting a patient's own immune cells and loading them with these AML-specific peptides to prime a robust T-cell response [2]. Once activated, CD8+ cytotoxic T lymphocytes (CTLs) recognize the MHC-I-peptide complex on AML blasts via their T-cell receptors (TCRs), triggering targeted cell death through the release of perforin and granzymes [4]. This interaction is highly specific, depending on both the particular HLA allele and the unique peptide sequence, making it a cornerstone of personalized immunotherapy and TCR-based drug development [3, 4]. The use of autologous dendritic cells ensures that the immune system is primed against the exact MHC-peptide combinations present in the patient's own tumor environment [2, 5].

Other names

HLA-peptide complexpMHCPeptide-MHC complexAntigen-MHC complexMHC-I-antigen complex

Presentation of leukemia-associated antigens to CD8+ T cells, facilitating the formation of an immunological synapse and subsequent T-cell mediated lysis of AML blasts.